214 related articles for article (PubMed ID: 31176270)
1. Ovarian cancer relapse: From the latest scientific evidence to the best practice.
Luvero D; Plotti F; Aloisia A; Montera R; Terranova C; Carlo De Cicco Nardone ; Scaletta G; Lopez S; Miranda A; Capriglione S; Gatti A; Pierluigi Benedetti Panici ; Angioli R
Crit Rev Oncol Hematol; 2019 Aug; 140():28-38. PubMed ID: 31176270
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapies for treatment of recurrent ovarian cancer.
Grisham RN; Hyman DM; Iyer G
Clin Adv Hematol Oncol; 2014 Mar; 12(3):158-62. PubMed ID: 24927263
[TBL] [Abstract][Full Text] [Related]
3. The changing landscape of therapeutic strategies for recurrent ovarian cancer.
Baumann KH; Wagner U; du Bois A
Future Oncol; 2012 Sep; 8(9):1135-47. PubMed ID: 23030488
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in the management of women with ovarian cancer.
Eltabbakh GH
Minerva Ginecol; 2004 Feb; 56(1):81-9. PubMed ID: 14973412
[TBL] [Abstract][Full Text] [Related]
5. Role of chemotherapy in epithelial ovarian cancer.
Markman M
Minerva Ginecol; 2011 Jun; 63(3):287-97. PubMed ID: 21654613
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapy for ovarian cancer: the rapidly evolving landscape of PARP inhibitor use.
Walsh C
Minerva Ginecol; 2018 Apr; 70(2):150-170. PubMed ID: 28994564
[TBL] [Abstract][Full Text] [Related]
7. Ovarian cancer: a focus on management of recurrent disease.
Herzog TJ; Pothuri B
Nat Clin Pract Oncol; 2006 Nov; 3(11):604-11. PubMed ID: 17080178
[TBL] [Abstract][Full Text] [Related]
8. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
9. [The molecular biology of epithelial ovarian cancer].
Leary A; Pautier P; Tazi Y; Morice P; Duvillard P; Gouy S; Uzan C; Gauthier H; Balleyguier C; Lhommé C
Bull Cancer; 2012 Dec; 99(12):1161-73. PubMed ID: 23238064
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapy in ovarian cancer.
Lim HJ; Ledger W
Womens Health (Lond); 2016 Jun; 12(3):363-78. PubMed ID: 27215391
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of epithelial ovarian cancer].
Langmár Z; Csömör S
Orv Hetil; 2006 Aug; 147(34):1627-32. PubMed ID: 17017677
[TBL] [Abstract][Full Text] [Related]
12. Update on the management and the role of intraperitoneal chemotherapy for ovarian cancer.
Teo MC
Curr Opin Obstet Gynecol; 2014 Feb; 26(1):3-8. PubMed ID: 24247932
[TBL] [Abstract][Full Text] [Related]
13. Second-line treatment of first relapse recurrent ovarian cancer.
Chua TC; Liauw W; Robertson G; Morris DL
Aust N Z J Obstet Gynaecol; 2010 Oct; 50(5):465-71. PubMed ID: 21039382
[TBL] [Abstract][Full Text] [Related]
14. New developments in molecular targeted therapy of ovarian cancer.
Guan LY; Lu Y
Discov Med; 2018 Nov; 26(144):219-229. PubMed ID: 30695681
[TBL] [Abstract][Full Text] [Related]
15. Ovarian cancer: diagnostic, biological and prognostic aspects.
Davidson B; Tropé CG
Womens Health (Lond); 2014 Sep; 10(5):519-33. PubMed ID: 25335543
[TBL] [Abstract][Full Text] [Related]
16. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.
Sui H; Shi C; Yan Z; Li H
Drug Des Devel Ther; 2015; 9():3183-90. PubMed ID: 26124641
[TBL] [Abstract][Full Text] [Related]
17. Treatment of ovarian cancer beyond chemotherapy: are we hitting the target?
Garces ÁH; Dias MS; Paulino E; Ferreira CG; de Melo AC
Cancer Chemother Pharmacol; 2015 Feb; 75(2):221-34. PubMed ID: 25212538
[TBL] [Abstract][Full Text] [Related]
18. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
[TBL] [Abstract][Full Text] [Related]
19. "Recurrence within 6 months of platinum therapy": an adequate definition of "platinum-refractory" ovarian cancer?
Markman M
Gynecol Oncol; 1998 May; 69(2):91-2. PubMed ID: 9600812
[No Abstract] [Full Text] [Related]
20. Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience.
Dizon DS; Dupont J; Anderson S; Sabbatini P; Hummer A; Aghajanian C; Spriggs D
Gynecol Oncol; 2003 Dec; 91(3):584-90. PubMed ID: 14675681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
